Alessandra Raimondi

10PUBLICATIONS
53CO-AUTHORS
Predictive and prognostic markersMolecular targetsOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Haematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 28, 2025
Primary tumor sidedness and negative hyperselection to modulate anti-EGFR-based maintenance strategies in patients with RAS wild-type metastatic colorectal cancer: individual patient data pooled analysis of two randomized clinical trials.

Alexej Ballhausen, Federica Morano, Arndt Stahler

|Aug 23, 2023
Negative Hyperselection of Patients with HER2+ and RAS Wild-Type Metastatic Colorectal Cancer Receiving Dual HER2 Blockade: the PRESSING-HER2 Study.

Giovanni Randon, Yoshiaki Nakamura, Rona Yaeger

|Feb 08, 2023
Fatty acid synthase as a new therapeutic target for HER2-positive gastric cancer.

Lorenzo Castagnoli, Simona Corso, Alma Franceschini

|Nov 22, 2022
HER2 Copy Number and Resistance Mechanisms in Patients with HER2-positive Advanced Gastric Cancer Receiving Initial Trastuzumab-based Therapy in JACOB Trial.

Filippo Pietrantonio, Paolo Manca, Sara Erika Bellomo

|Jun 09, 2022
Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial.

Alessandra Raimondi, Giovanni Randon, Michele Prisciandaro

|Nov 23, 2021
Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study.

Paolo Manca, Salvatore Corallo, Sara Lonardi

Pageof 2

Frequent Collaborators

7 joint publications

Filippo Pietrantonio

2 joint publications

Silvia Giordano

2 joint publications

Maria Di Bartolomeo

2 joint publications

Sara Lonardi